3-氨基-2-溴-6-氯吡啶 | 1050501-88-6

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-氨基-2-溴-6-氯吡啶
• 英文名称: 2-bromo-6-chloropyridin-3-amine
• CAS: 1050501-88-6
• 化学式: C₅H₄BrClN₂
• 分子量: 207.457
• InChiKey: OPKKXWUGXHSFQI-UHFFFAOYSA-N

物化性质

• 沸点：
  330.3±37.0 °C(Predicted)
• 密度：
  1.834

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  应存放在室温环境中，避免光照，并保存在惰性气体中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Amino-2-bromo-6-chloropyridine
Synonyms: 2-Bromo-6-chloropyridin-3-amine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Amino-2-bromo-6-chloropyridine
CAS number: 1050501-88-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H4BrClN2
Molecular weight: 207.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

3-氨基-2-溴-6-氯吡啶可用作医药合成中间体。

危险处理

若吸入3-氨基-2-溴-6-氯吡啶，请将患者移至空气新鲜处；如皮肤沾染，应立即脱去污染衣物，并用肥皂水和清水彻底冲洗皮肤，如有不适，请就医；如眼睛接触到该物质，需分开眼睑，使用流动清水或生理盐水冲洗，并立即就医；若误食，请立即漱口，禁止催吐，并尽快就医。

反应信息

• 作为反应物：
  描述：

  3-氨基-2-溴-6-氯吡啶 在 硫酸 、 palladium diacetate 、 三乙胺 、 三苯基膦 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 methyl 5-chloro-1H-pyrrolo[3,2-b]pyridine-2-carboxylate
  参考文献：
  名称：

  [EN] 1,3 -DIHYDRO- 2H-BENZIMIDAZOL- 2 -ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS
  [FR] DÉRIVÉS DE 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE SUBSTITUÉS PAR DES HÉTÉROCYCLES UTILISÉS COMME AGENTS ANTIVIRAUX CONTRE LE VIRUS RESPIRATOIRE SYNCYTIAL

  摘要：

  本发明涉及具有具有式（I）的杂环取代的新型1,3-二氢-2H-苯并咪唑-2-酮衍生物及其立体异构体，以及其药学上可接受的加盐物和溶剂化物，其中R4、R5、Z和Het在权利要求中定义的含义。根据本发明的化合物可用作抑制呼吸道合胞病毒（RSV）复制的药物。本发明还涉及制备这种新型化合物、包含这些化合物的组合物以及用于治疗呼吸道合胞病毒感染的化合物。

  公开号：

  WO2013186333A1
• 作为产物：
  描述：

  2-氯-5-氨基吡啶 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 乙腈 为溶剂， 反应 0.08h， 以93%的产率得到3-氨基-2-溴-6-氯吡啶
  参考文献：
  名称：

  固态硫族键合超分子纳米带的取代基控制剪裁

  摘要：

  在这项工作中，我们设计并合成了固态的超分子带中排列的超分子2,5取代硫属元素唑并[5,4-β]吡啶（CGP）合成子。概述了仔细选择CGP支架上2位和5位取代基的组合，以通过包含硫族元素和氢键的多种杂化相互作用完成超分子材料。取决于取代基的空间和电子性质，已经实现了不同的固态排列。在5-位的不同部分中，恶唑单元通过Pd催化的交叉偶联反应掺入到Se和Te同源物上，并且在固态下始终获得超分子带状组织。

  DOI：

  10.1021/acs.cgd.0c01318

文献信息

• [EN] 6-(MORPHOLIN-4-YL)-PYRIDIN-2-YL-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS M-TOR INHIBITORS<br/>[FR] DÉRIVÉS DE 6-(MORPHOLIN-4-YL)-PYRIDIN-2-YL-1H-PYRROLO[3,2-B]PYRIDINE EN TANT QU'INHIBITEURS DE M-TOR
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2019115640A1

  公开（公告）日：2019-06-20

  The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, L and A are as defined in the description and claims, or pharmaceutically acceptable salts thereof having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions including a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.

  该发明涉及式(I)的化合物，其中R1、R2、R3、R4、L和A如描述和索赔中所定义，或其药学上可接受的盐，具有mTOR激酶抑制剂活性。该发明还涉及包括式(I)的化合物或其药学上可接受的盐的药物组合物，以及在治疗中使用式(I)的化合物或其药学上可接受的盐，包括治疗需要mTOR激酶抑制剂活性的疾病或症状，特别是治疗特发性肺纤维化。
• [EN] BIPHENYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDÈNE-AMINE À SUBSTITUTION BIPHÉNYLE
  申请人：NOVARTIS AG

  公开号：WO2011157787A1

  公开（公告）日：2011-12-22

  The invention relates to new derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of one or more IGF-1 R mediated disorders or diseases.

  这项发明涉及公式（I）的新衍生物，其中取代基如规范中所定义；制备这种衍生物的方法；包括这种衍生物的药物组合物；将这种衍生物用作药物；将这种衍生物用于治疗一个或多个IGF-1 R介导的疾病。
• [EN] TETRAHYDROBENZOFURO[2,3-C]PYRIDINE AND BETA-CARBOLINE COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES<br/>[FR] COMPOSÉS DE TÉTRAHYDROBENZOFURO[2,3-C]PYRIDINE ET DE BÊTA-CARBOLINE POUR LE TRAITEMENT, LE SOULAGEMENT OU LA PRÉVENTION DE TROUBLES ASSOCIÉS À DES AGRÉGATS DE PROTÉINE TAU
  申请人：AC IMMUNE SA

  公开号：WO2019233883A1

  公开（公告）日：2019-12-12

  The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

  本发明涉及一种可以用于治疗、缓解或预防与Tau（微管相关单元）蛋白聚集相关的一组疾病和异常的新化合物（I）的公式。这些疾病和异常包括但不限于神经原纤维缠结（NFTs），如阿尔茨海默病（AD）。
• ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
  申请人：Universal Display Corporation

  公开号：US20160240800A1

  公开（公告）日：2016-08-18

  A compound having a Pt tetradentate structure selected from the group consisting of is provided. In the structures of Formula 1 and Formula 2, rings C and D each independently represent 5- or 6-membered carbocyclic or heterocyclic ring; L 1 , L 2 , and L 3 are each independently a direct bond, BR, NR, PR, O, S, Se, C═O, S═O, SO 2 , SiRR′, GeRR′, alkyl, cycloalkyl, or a combination thereof; the sum of n1 and n2 is 1 or 2; X is selected from NR E , O, S, and Se; X 3 and X 4 each independently carbon or nitrogen; and one of Q 1 , Q 3 , and Q 4 is oxygen, and the remaining two of Q 1 , Q 3 , and Q 4 each represents a direct bond. Formulations and devices, such as an OLEDs, that include the compound of Formulas 1 and 2 are also described.

  提供了一种从包括的群体中选择的具有Pt四齿结构的化合物。在公式1和公式2的结构中，环C和环D分别独立表示5-或6-成员碳环或杂环；L1、L2和L3分别独立表示直接键，BR，NR，PR，O，S，Se，C═O，S═O，SO2，SiRR′，GeRR′，烷基，环烷基或它们的组合；n1和n2的和为1或2；X从NRE，O，S和Se中选择；X3和X4分别独立表示碳或氮；Q1、Q3和Q4中的一个是氧，剩下的两个Q1、Q3和Q4中的每一个表示直接键。还描述了包括公式1和公式2的化合物的配方和设备，如OLEDs。
• [EN] RSV ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX CONTRE LE VRS
  申请人：JANSSEN R & D IRELAND

  公开号：WO2014060411A1

  公开（公告）日：2014-04-24

  Inhibitors of RSV replication of formula RI including stereochemically isomeric forms, and salts or solvates thereof, wherein R22, W, Q, V, Z p,s,and Het have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other RSV inhibitors, in RSV therapy.

  RSV复制抑制剂的公式RI包括立体化学同分异构体形式，以及其盐或溶剂合物，其中R22、W、Q、V、Z、p、s和Het的含义如本文所定义。本发明还涉及制备所述化合物的方法，含有它们的药物组合物以及它们在RSV治疗中单独或与其他RSV抑制剂结合使用的用途。